Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20106931 | 0.79 | — | — | |
| SCHEMBL29208918 | 0.75 | NPY5R (0.33) | — | |
| SCHEMBL2224796 | 0.73 | — | — | |
| SCHEMBL6050967 | 0.72 | NPY5R (0.36) | — | |
| SCHEMBL6050914 | 0.72 | NPY5R (0.36) | — | |
| SCHEMBL974911 | 0.69 | TSHR (0.36) | KMT2ANPSR1 | |
| SCHEMBL4793302 | 0.69 | — | — | |
| SCHEMBL883355 | 0.69 | — | — | |
| SCHEMBL3923881 | 0.69 | — | — | |
| SCHEMBL18709722 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116710461-A | Sulfonylurea NLRP3 inflammation corpuscle inhibitor | 维纳拓尔斯制药公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-2086995-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086963-A2 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064066-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1904516-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1879910-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1863793-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007008657-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1629000-A4 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006122188-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1629000-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |